1. Home
  2. AQST vs BWAY Comparison

AQST vs BWAY Comparison

Compare AQST & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aquestive Therapeutics Inc.

AQST

Aquestive Therapeutics Inc.

N/A

Current Price

$4.18

Market Cap

504.0M

Sector

Health Care

ML Signal

N/A

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

N/A

Current Price

$14.31

Market Cap

578.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AQST
BWAY
Founded
2004
2003
Country
United States
Israel
Employees
N/A
129
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
504.0M
578.5M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
AQST
BWAY
Price
$4.18
$14.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$9.00
$13.25
AVG Volume (30 Days)
1.5M
107.6K
Earning Date
05-01-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$67,430,000.00
N/A
Revenue This Year
$10.08
$309.69
Revenue Next Year
$49.60
$26.21
P/E Ratio
N/A
$81.98
Revenue Growth
0.77
N/A
52 Week Low
$2.94
$10.81
52 Week High
$7.55
$26.63

Technical Indicators

Market Signals
Indicator
AQST
BWAY
Relative Strength Index (RSI) 53.52 43.12
Support Level $3.95 $11.90
Resistance Level $4.38 $14.65
Average True Range (ATR) 0.15 0.62
MACD 0.02 -0.03
Stochastic Oscillator 73.33 27.37

Price Performance

Historical Comparison
AQST
BWAY

About AQST Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: